Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Feb 17, 2021 7:42am
126 Views
Post# 32582363

RE:RE:RE:RE:RE:Seeking alpha write up on madrigal

RE:RE:RE:RE:RE:Seeking alpha write up on madrigal Nothing stop us to try but I don't think it's going to change their mind, this dude as per disclaimer didn't have any position but will possibly go long in the next 72 hours!! He will not correct his report also he didn't only left out THTX only but some other players in the field too.
His report was heavily biased towards one company of course we can comment on his report but I think the best route is the company contract folks like him directly and then we can write many comments related to the report.
Also I don't think he accidentally left out other companies.
Rarly when there is an article about THTX I always add my insights on the comment section, every little thing helps. I really like your proactive thinking, this company needs a lot more investors like yourself....

MHemorrhage wrote:

https://twitter.com/hemorrhage_m/status/1362006609401057282

Just tweeted him. What stops us from contacting every author that (accidently) omits THTX as Phase III NASH player?

 

scarlet1967 wrote:

 

 
The report you mentioned was written by a guy with following bio.
I write about Biotech, Pharma and Healthcare stocks and share investment tips. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. I'm on twitter @edmundingham
 




<< Previous
Bullboard Posts
Next >>